PMID- 19368933
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20151119
IS  - 0025-7753 (Print)
IS  - 0025-7753 (Linking)
VI  - 132
IP  - 14
DP  - 2009 Apr 18
TI  - [Prognostic value study of lung cancer molecular markers].
PG  - 529-36
LID - 10.1016/j.medcli.2008.10.060 [doi]
AB  - BACKGROUND AND OBJECTIVE: The aim of this study was to determine the prognostic 
      value of molecular markers (proteins) of different paths of lung cancer 
      development in patients with non small cell lung carcinoma (NSCLC) in initial 
      stages. MATERIAL AND METHOD: Observational, cohort study in patients with NSCLC 
      that was initially treated surgically in our hospital between October 1993 and 
      September 1997. Thirty-two proteins were selected. The study consisted of the 
      elaboration of tissue arrays with samples from resected tumour, using a 
      semiquantitative immunohistochemical study. A prognosis analysis was done with 
      the expression of each protein and calculation of the overall 5-year survival 
      rate. The Wilcoxon-Gehan and Log-Rank tests were used for statistical 
      comparisons, with p<.05 being considered to indicate a significant result. 
      RESULTS: One hundred and forty six patients were studied. The overall 5-year 
      survival rate was 37.7%. From 32 proteins studied, three were statistically 
      associated with overall 5-year survival rate. RB protein expression in resected 
      NSCLC was a positive prognostic factor (P=.01). P27 (P=.03) and Ki67 (P=.04) 
      expression in resected NSCLC were negative prognostic factors. There was no 
      protein with prognostic value in epidermoid tumours. CONCLUSIONS: We found three 
      proteins with long-term prognostic value in the long-term in the general 
      population and five adenocarcinoma prognostic proteins in our study of resected 
      non-small cell lung cancer (NSCLC). In the future, genetic-molecular factors 
      should be included along with anatomical (TNM staging) and clinical factors in a 
      multidimensional lung cancer staging.
FAU - Garcia Lujan, Ricardo
AU  - Garcia Lujan R
AD  - Servicio de Neumologia, Hospital Universitario 12 de Octubre, Madrid, Espana. 
      rglujan@hotmail.com
FAU - Conde Gallego, Esther
AU  - Conde Gallego E
FAU - Lopez Rios, Fernando
AU  - Lopez Rios F
FAU - Martin De Nicolas, Jose Luis
AU  - Martin De Nicolas JL
FAU - Sanchez Cespedes, Montserrat
AU  - Sanchez Cespedes M
FAU - Garcia Quero, Cristina
AU  - Garcia Quero C
FAU - Lopez Encuentra, Angel
AU  - Lopez Encuentra A
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Valor pronostico de los marcadores moleculares en el carcinoma broncogenico.
DEP - 20090414
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*chemistry/metabolism/*mortality
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*chemistry/metabolism/*mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*analysis/biosynthesis
MH  - Prognosis
MH  - Survival Rate
EDAT- 2009/04/17 09:00
MHDA- 2009/08/21 09:00
CRDT- 2009/04/17 09:00
PHST- 2008/05/28 00:00 [received]
PHST- 2008/10/24 00:00 [accepted]
PHST- 2009/04/17 09:00 [entrez]
PHST- 2009/04/17 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
AID - S0025-7753(09)00430-8 [pii]
AID - 10.1016/j.medcli.2008.10.060 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2009 Apr 18;132(14):529-36. doi: 10.1016/j.medcli.2008.10.060. 
      Epub 2009 Apr 14.